Key result
Glycyrrhizic acid administration significantly improved insulin sensitivity (HOMA-IR 0.12 vs 0.23, p<0.05) and reduced tissue lipid deposition in high-fat diet-induced obese rats.
Why the study?
Does glycyrrhizic acid improve lipoprotein lipase expression, insulin sensitivity, and lipid profiles in high-fat diet-induced obese rats?
Does glycyrrhizic acid improve lipoprotein lipase expression, insulin sensitivity, and lipid profiles in high-fat diet-induced obese rats?
Absolute Event Rate: 0.12% vs 0.23%
p-value: p=<0.05
Glycyrrhizic acid ameliorates dyslipidemia and insulin resistance in high-fat diet-induced obese rats, likely by selectively up-regulating lipoprotein lipase expression in non-hepatic tissues.
Hypothesis-generating for glycyrrhizic acid in obesity models; human trials required before any clinical consideration.
BACKGROUND: The metabolic syndrome, known also as the insulin resistance syndrome, refers to the clustering of several risk factors for atherosclerotic cardiovascular disease. Dyslipidaemia is a hallmark of the syndrome and is associated with a whole body reduction in the activity of lipoprotein lipase (LPL), an enzyme under the regulation of the class of nuclear receptors known as peroxisome proliferator-activated receptor (PPAR). Glycyrrhizic acid (GA), a triterpenoid saponin, is the primary bioactive constituent of the roots of the shrub Glycyrrhiza glabra. Studies have indicated that triterpenoids could act as PPAR agonists and GA is therefore postulated to restore LPL expression in the insulin resistant state. RESULTS: Oral administration of 100 mg/kg of GA to high-fat diet-induced obese rats for 28 days led to significant reduction in blood glucose concentration and improvement in insulin sensitivity as indicated by the homeostasis model assessment of insulin resistance (HOMA-IR) (p < 0.05). LPL expression was up-regulated in the kidney, heart, quadriceps femoris, abdominal muscle and the visceral and subcutaneous adipose tissues but down-regulated in the liver--a condition in reverse to that seen in high-fat diet-induced obese rats without GA. With regard to lipid metabolism, GA administration led to significant hypotriglyceridemic and HDL-raising effects (p < 0.05), with a consistent reduction in serum free fatty acid, total cholesterol and LDL cholesterol and significant decrease in tissue lipid deposition across all studied tissue (p < 0.01). CONCLUSION: In conclusion, GA may be a potential compound in improving dyslipidaemia by selectively inducing LPL expression in non-hepatic tissues. Such up-regulation was accompanied by a GA-mediated improvement in insulin sensitivity, which may be associated with a decrease in tissue lipid deposition. The HDL-raising effect of GA suggests the antiatherosclerotic properties of GA.
No takes yet. Share an insight, caveat, or question.
Eu et al. (2010) studied High-fat diet-induced obesity (n=24). Glycyrrhizic acid vs. High-fat diet without glycyrrhizic acid was evaluated on Homeostasis model assessment of insulin resistance (HOMA-IR) (p=<0.05). Glycyrrhizic acid administration significantly improved insulin sensitivity (HOMA-IR 0.12 vs 0.23, p<0.05) and reduced tissue lipid deposition in high-fat diet-induced obese rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: